Vijayasar

<h3> Absolute Contraindications of Vijayasar </h3> <h4> 1) Concomitant use with insulin or insulin-secretagogues (e.g., sulfonylureas, meglitinides) - (risk: severe hypoglycaemia)</h4> <ul> <li>🩺</li> <li>Recommendation: Do not take Vijayasar extracts together with insulin or strong blood-glucose-lowering drugs unless under strict medical supervision and with frequent blood-glucose monitoring.</li> <li>Reasoning: Multiple animal and experimental studies show P. marsupium extracts lower fasting and postprandial glucose and can increase insulin levels or improve glucose uptake; combining this effect with prescription hypoglycemic agents can produce dangerously low blood sugar.</li> <li>Scientific_Study_Title: The study of aqueous extract of Pterocarpus marsupium Roxb. on cytokine TNF-α in type 2 diabetic rats.</li> <li>Scientific_Study_Authors: Kirana Halagappa, HN Girish, BP Srinivasan.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/21189913/</li> <li>Scientific_Study_Excerpt: <p>Paraphrased summary from the study: In a streptozotocin-induced type 2 diabetic rat model, oral aqueous extracts of Pterocarpus marsupium (100 and 200 mg/kg) significantly reduced both fasting and postprandial blood glucose compared with diabetic controls, and the higher dose showed the larger effect. The extract also lowered elevated inflammatory cytokine TNF-α and improved body weight relative to untreated diabetic rats. The authors compared effects to a gliclazide standard and documented glucose-lowering and anti-inflammatory changes consistent with an antidiabetic pharmacological profile.</p> <p>This experimental evidence supports the drug-like glucose-lowering capability of P. marsupium and the need for caution when it is combined with other glucose-lowering medications due to hypoglycemia risk.</p> </li> </ul> <h4> 2) Concurrent use with drugs predominantly cleared by UGT1A9 or CYP2C8 (examples: some NSAIDs, repaglinide/pioglitazone metabolites) - (risk: altered drug levels/toxicity)</h4> <ul> <li>⚠️</li> <li>Recommendation: Avoid unsupervised concurrent use of high-dose pterostilbene/P. marsupium extracts with medications primarily metabolized by UGT1A9 or CYP2C8; consult a clinician or pharmacist for dose adjustment and monitoring.</li> <li>Reasoning: Pterostilbene from P. marsupium inhibits several drug-metabolizing enzymes in vitro (notably UGT1A9 and, in some assays, CYP2C8/UGT1A6), which can raise blood levels of coadministered drugs cleared by those pathways, increasing side-effect risk.</li> <li>Scientific_Study_Title: Pterostilbene supplements carry the risk of drug interaction via inhibition of UDP-glucuronosyltransferases (UGT) 1A9 enzymes.</li> <li>Scientific_Study_Authors: Lili Jiang, Zhongmin Zhang, Yangliu Xia, Zhen Wang, Xiaoyu Wang, Shujuan Wang, Zhe Wang, Yong Liu.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/31812603/</li> <li>Scientific_Study_Excerpt: <p>Paraphrased summary from the study: In vitro experiments using human liver microsomes demonstrated that pterostilbene potently inhibited several UGT isoforms (including UGT1A9) and showed moderate inhibition of other UGTs. Kinetic analyses estimated IC50/Ki values consistent with potential in vivo effects at supplement doses. The authors' predictive modeling suggested that coadministration of pterostilbene supplements at typical supplement doses (≈100 mg/day or higher) could increase systemic exposure (AUC) of drugs primarily cleared by UGT1A9 by clinically meaningful amounts (≈50% or more), creating a risk for drug accumulation and toxicity.</p> <p>The study supports caution when combining pterostilbene-containing Vijayasar preparations with medicines dependent on UGT1A9 clearance such as some analgesics, antidiabetics, and other narrow-therapeutic-index drugs.</p> </li> </ul> <h4> 3) Patients with uncontrolled hyperlipidemia or those at high atherosclerotic risk using high-dose pterostilbene isolates</h4> <ul> <li>🧾</li> <li>Recommendation: If you have high LDL or established cardiovascular disease, avoid using concentrated pterostilbene supplements without medical advice and lipid monitoring; use of whole-herb preparations should be discussed with your clinician.</li> <li>Reasoning: In at least one randomized human trial, pterostilbene (a major bioactive in P. marsupium) when given alone increased LDL cholesterol compared with placebo; LDL changes may be clinically important in people at cardiovascular risk.</li> <li>Scientific_Study_Title: Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial.</li> <li>Scientific_Study_Authors: McCormack, M., et al. (study group authors listed in full on paper).</li> <li>Scientific_Study_Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099343/</li> <li>Scientific_Study_Excerpt: <p>Paraphrased summary from the trial: In a randomized, double-blind placebo-controlled study of adults with elevated cholesterol, subjects receiving pterostilbene monotherapy (various doses) experienced a statistically significant increase in LDL cholesterol (mean increase ≈17 mg/dL) over 6-8 weeks compared with placebo; this LDL rise was not observed when pterostilbene was combined with grape extract or when subjects were already on cholesterol-lowering medication. The study also reported reductions in blood pressure with higher dose pterostilbene.</p> <p>The trial data indicate that high-dose, purified pterostilbene (often used as a supplement extracted from P. marsupium) can raise LDL in some people and so should be avoided or used with care in those with existing hyperlipidemia or high cardiovascular risk.</p> </li> </ul> <h3> Relative Contraindications of Vijayasar </h3> <h4> 1) Pregnancy and breastfeeding</h4> <ul> <li>🤱</li> <li>Recommendation: Avoid Vijayasar extracts (and pterostilbene supplements) during pregnancy and breastfeeding because safety data are insufficient; consult an obstetric provider if exposure has occurred.</li> <li>Reasoning: Human safety trials of pterostilbene/P. marsupium have been done in healthy adults but exclude pregnant and lactating women; reproductive and developmental safety data for P. marsupium are lacking, so risk cannot be ruled out.</li> <li>Scientific_Study_Title: A Short-Term Safety Evaluation of Silbinol®-an extract from Pterocarpus marsupium in healthy adults: a randomized, double-blind, placebo-controlled study.</li> <li>Scientific_Study_Authors: S. R. et al. (see original paper for full author list: Silbinol® safety study authors).</li> <li>Scientific_Study_Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10483972/</li> <li>Scientific_Study_Excerpt: <p>Paraphrased summary from the study: The Silbinol® randomized safety trial tested a standardized pterostilbene extract (200 mg/day) in healthy adult volunteers for 60 days and found no clinically significant safety signals in routine labs or adverse events; however, the trial enrolled healthy non-pregnant adults and explicitly does not provide data on use in pregnancy or lactation. As a result, authors and regulatory practice advise avoiding such supplements in pregnancy due to absent reproductive safety data.</p> </li> </ul> <h4> 2) Significant liver impairment</h4> <ul> <li>⚕️</li> <li>Recommendation: Use only under specialist supervision with liver function monitoring, or avoid if moderate-to-severe hepatic impairment is present.</li> <li>Reasoning: Certain preclinical and subacute toxicology studies of pterostilbene/pterostilbene-related compounds showed dose-related hepatic findings in animals (e.g., modest liver weight change or enzyme effects at high doses) and in vitro enzyme inhibition indicates an impact on hepatic metabolism; compromised liver function raises the risk of accumulation and adverse effects.</li> <li>Scientific_Study_Title: Subacute oral toxicology and toxicokinetics of pterostilbene, a novel Top1/Tdp1 inhibiting agent (toxicokinetics paper documenting hepatic findings in rats).</li> <li>Scientific_Study_Authors: (see original article for full authorship-example toxicokinetics study authors listed in PubMed entry).</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35253568/</li> <li>Scientific_Study_Excerpt: <p>Paraphrased summary from the toxicokinetic report: In rodent repeated-dose studies, higher pterostilbene doses led to increased liver weight and mild histopathological changes in female animals at the highest dose tested; systemic exposure rose with dose. These preclinical signals indicate the liver is exposed and potentially responsive to higher pterostilbene doses, supporting caution in people with preexisting hepatic impairment because altered clearance could increase adverse outcomes.</p> </li> </ul> <h4> 3) Pediatric use (children)</h4> <ul> <li>🧒</li> <li>Recommendation: Avoid use in children unless recommended and supervised by a pediatric clinician; dosing and safety data are limited.</li> <li>Reasoning: Clinical safety studies of standardized pterostilbene/P. marsupium extracts have been performed in adults; pediatric pharmacology and safety are not established.</li> <li>Scientific_Study_Title: A Short-Term Safety Evaluation of Silbinol®-an extract from Pterocarpus marsupium in healthy adults.</li> <li>Scientific_Study_Authors: (see original paper for full author list).</li> <li>Scientific_Study_Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10483972/</li> <li>Scientific_Study_Excerpt: <p>Paraphrased summary from the study: The safety trial enrolled healthy adult volunteers and documented tolerability at 200 mg/day over 60 days; authors highlight the absence of pediatric data and so do not recommend extrapolating adult tolerability results to children. This gap supports a cautious, avoidance approach for pediatric use pending targeted pediatric studies.</p> </li> </ul>